FORCE's XRAYS program, funded by the CDC, is a reliable resource for young breast cancer survivors and high-risk women to navigate through breast cancer research related news and information.
FORCE developed our eXamining the Relevance of Articles for Young Survivors (XRAYS) program to empower young breast cancer survivors and high-risk women by providing tools for evaluating reports of new breast cancer-related research. Funded by the CDC, XRAYS will provide reviews and ratings of news media articles on breast cancer research to help young breast cancer survivors better understand research that is relevant to them. Learn more about the XRAYS program
Patients and health care providers are often concerned about how exercise affects lymphedema (swelling in the arm or hand) in breast cancer survivors or other women who have had lymph node biopsy at the time of mastectomy. Research on this topic has been mixed. A new study suggests that exercise after breast cancer treatment does not lead to lymphedema or worsen existing lymphedema. However, because this study was small, more work needs to be done to understand the relationship between exercise and lymphedema in cancer survivors. (2/22/17)
Finding new treatments that target triple-negative breast cancer is an area of great interest. An early step in developing these treatments is learning more about the biology of tumor in the laboratory. This study looked at how capsaicin, the spicy component of chili peppers, might work with a protein found in many cancers, including triple-negative breast cancer, to stop cancer cell growth. This is the first step in a long process towards developing new treatments for triple-negative breast cancer. (2/14/17)
Current tools used to calculate breast cancer risk make their estimations based on data from non-Hispanic white women and may not accurately predict breast cancer risk in women of other races and ethnicities. With further testing, a new risk assessment tool developed specifically for Hispanic women could more accurately predict breast cancer risk in women who do not have mutations in BRCA or other genes associated with hereditary breast cancer. (02/07/17)
Many people report memory or concentration problems, commonly known as “chemobrain,” during and after cancer treatment. New research shows that for some breast cancer patients these issues continue 6 months after treatment. Documentation of this well-known effect is a crucial first step in developing ways to limit and treat it. (02/02/17)